Actinogen Medical’s (ASX:ACW) chief medical officer, Dr Dana Hilt, has presented an academic poster to the Alzheimer’s Association International Conference (AAIC) in Amsterdam.
AAIC is a global forum to advance dementia science.
The Actinogen academic poster is titled Xanamem shows pro-cognitive activity with clinically meaningful effect sizes across three independent, placebo-controlled clinical trials.
The company said the poster and the associated abstract summarise data from three earlier Phase 1 and Phase 2a Xanamem trials and conclude that it displays activity in multiple domains of cognition, including attention, working memory, and executive function, with clinically meaningful effects in normal subjects and in patients with pTau-elevated mild Alzheimer’s disease.
“These data suggest Xanamem may be both a pro-cognitive drug and disease-modifying agent and guide design of future trials, including the upcoming XanaMIA Phase 2b trial in patients with early Alzheimer’s disease, due to treat its first patient prior to the end of 2023,” said the company.
Actinogen’s CEO and managing director Dr Steven Gourlay said, “Actinogen is excited to present its novel Phase 2a dataset that is one of the first to show that the blood pTau biomarker is a highly effective method for selection of patients with a progressive form of mild Alzheimer’s disease.
“In these patients, Xanamem showed multiple indications of both clinical benefit (slowed progression of CDR-SB which assesses clinical function) and tests of cognition. Xanamem has now shown precognitive effects in a number of studies. As a simulation of the upcoming 330-patient XanaMIA Phase 2b trial the data give us confidence in our study design, endpoints and patient selection criteria.”
